Myriad Genetics (NASDAQ:MYGN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.38 by 14 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 6 Brokerage Firms have advised hold. 2 Analysts have rated it as strong sell.
Other Equity analysts have also commented on the company shares. Major Brokerage house, Avondale Partners maintains its ratings on Myriad Genetics (NASDAQ:MYGN). In the latest research report, Avondale Partners lowers the target price from $50 per share to $47 per share. According to the latest information available, the shares are now rated Market Outperform by the analysts at the agency. The rating by the firm was issued on May 4, 2016.
Myriad Genetics (NASDAQ:MYGN): 9 Analyst have given the stock of Myriad Genetics (NASDAQ:MYGN) a near short term price target of $39.67. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $7.87. The higher price target estimate is at $50 while the lower price estimates are fixed at $25.
Myriad Genetics (NASDAQ:MYGN) witnessed a decline in the market cap on Tuesday as its shares dropped 0.68% or 0.21 points. After the session commenced at $31.08, the stock reached the higher end at $31.32 while it hit a low of $30.57. With the volume soaring to 924,709 shares, the last trade was called at $30.72. The company has a 52-week high of $46.24. The company has a market cap of $2,160 million and there are 70,298,970 shares in outstanding. The 52-week low of the share price is $30.01.
Shares of Myriad Genetics, Inc. appreciated by 0.92% during the last five trading days but lost 10.1% on a 4-week basis. Myriad Genetics, Inc. has dropped 17.35% during the last 3-month period . Year-to-Date the stock performance stands at -28.82%.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.